Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Tiziana Life Sciences

TLSA ↗$0.62 USD
#Neurology#Autoimmune#Neuroinflammation

Clinical-stage biotechnology company developing next-generation immunomodulatory therapies using alternative routes of administration, focusing on intranasally delivered foralumab for neurodegenerative and autoimmune diseases.

Company Info

Sector:Antibodies
Headquarters:New York, NY, USA
Founded:1998
Website:www.tizianalifesciences.com/

Clinical Development Pipeline

Foralumab (Intranasal)

Target: CD3
Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Foralumab (Intranasal)

Target: CD3
Alzheimer's Disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Foralumab (Intranasal)

Target: CD3
Amyotrophic Lateral Sclerosis (ALS)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Gabriele Cerrone

Executive Chairman & Founder

Ivor Elrifi

Chief Executive Officer

Careers & Job Openings

Clinical Trial Manager

Clinical Development
New York, NY
Apply Now →